PDF(Pubmed)
Abstract：
UNASSIGNED: Administering azathioprine or infliximab for UC and AS treatment carries a significant risk of adverse reactions. Here, we present the case diagnosed with UC and AS, who received treatment with azathioprine and infliximab for 10 months, and subsequently developed drug-induced myopathy affecting the right vastus medialis muscle.
UNASSIGNED: Drug-induced myopathy is an uncommon form of muscle injury that can arise in patients without preexisting muscle conditions when exposed to therapeutic doses of certain medications. Administering azathioprine or infliximab for ulcerative colitis (UC) and ankylosing spondylitis (AS) treatment carries a significant risk of adverse reactions, including drug-induced myopathy and increased susceptibility to opportunistic infections. However, occurrences of myopathy induced by the combination of azathioprine and infliximab are rarely reported in clinical practice. Here, we present the case of a 37-year-old male patient diagnosed with UC and AS, who received treatment with azathioprine and infliximab for 10 months. Despite the resolution of symptoms and improvement in intestinal mucosal inflammation observed via endoscopy, the patient subsequently developed drug-induced myopathy affecting the right vastus medialis muscle.
UNASSIGNED: Drug-induced myopathy is an uncommon form of muscle injury that can arise in patients without preexisting muscle conditions when exposed to therapeutic doses of certain medications. Administering azathioprine or infliximab for ulcerative colitis (UC) and ankylosing spondylitis (AS) treatment carries a significant risk of adverse reactions, including drug-induced myopathy and increased susceptibility to opportunistic infections. However, occurrences of myopathy induced by the combination of azathioprine and infliximab are rarely reported in clinical practice. Here, we present the case of a 37-year-old male patient diagnosed with UC and AS, who received treatment with azathioprine and infliximab for 10 months. Despite the resolution of symptoms and improvement in intestinal mucosal inflammation observed via endoscopy, the patient subsequently developed drug-induced myopathy affecting the right vastus medialis muscle.
摘要：
■服用硫唑嘌呤或英夫利昔单抗治疗UC和AS有明显的不良反应风险。这里,我们目前的病例诊断为UC和AS，接受硫唑嘌呤和英夫利昔单抗治疗10个月的患者，随后发展为药物诱发的肌病，影响右侧股内侧肌。
药物诱发的肌病是一种罕见的肌肉损伤形式，在没有预先存在的肌肉疾病的患者中，当暴露于治疗剂量的某些药物时，会出现这种情况。使用硫唑嘌呤或英夫利昔单抗治疗溃疡性结肠炎（UC）和强直性脊柱炎（AS）具有明显的不良反应风险。包括药物诱发的肌病和机会性感染的易感性增加。然而,在临床实践中，很少报道由硫唑嘌呤和英夫利昔单抗联合使用引起的肌病的发生。这里,我们介绍了一个37岁的男性患者诊断为UC和AS，接受硫唑嘌呤和英夫利昔单抗治疗10个月。尽管通过内窥镜观察到症状的缓解和肠粘膜炎症的改善，患者随后发展为药物诱发的肌病，影响了右股内侧肌。
药物诱发的肌病是一种罕见的肌肉损伤形式，在没有预先存在的肌肉疾病的患者中，当暴露于治疗剂量的某些药物时，会出现这种情况。使用硫唑嘌呤或英夫利昔单抗治疗溃疡性结肠炎（UC）和强直性脊柱炎（AS）具有明显的不良反应风险。包括药物诱发的肌病和机会性感染的易感性增加。然而,在临床实践中，很少报道由硫唑嘌呤和英夫利昔单抗联合使用引起的肌病的发生。这里,我们介绍了一个37岁的男性患者诊断为UC和AS，接受硫唑嘌呤和英夫利昔单抗治疗10个月。尽管通过内窥镜观察到症状的缓解和肠粘膜炎症的改善，患者随后发展为药物诱发的肌病，影响了右股内侧肌。
